Abstract: A control system for a double-acting air cylinder of an agricultural implement includes a valve assembly configured to control a base end air pressure and a rod end air pressure of the double-acting air cylinder. The control system also includes a controller communicatively coupled to the valve assembly. The controller is configured to determine a target base end air pressure and a target rod end air pressure based on a target force of the double-acting air cylinder and a target damping factor of the double-acting air cylinder. The controller is also configured to control the valve assembly such that a first difference between the base end air pressure and the target base end air pressure is less than a first threshold value and a second difference between the rod end air pressure and the target rod end air pressure is less than a second threshold value.

Abstract: The present disclosure relates to compositions of matter, methods, and systems for analyzing polymeric macromolecules, including polymeric macromolecules such as peptides, polypeptides, and proteins.

Abstract: The present disclosure provides methods and compositions for multiplex quantitation. In some aspects, methods and compositions are provided for quantitation of nucleic acid targets from a biological sample. The disclosed methods may be useful in identifying or detecting genetic abnormalities from a subject.

Abstract: The present disclosure provides methods and compositions for multiplex quantitation. In some aspects, methods and compositions are provided for quantitation of nucleic acid targets from a biological sample. The disclosed methods may be useful in identifying or detecting genetic abnormalities from a subject.

Abstract: The present disclosure provides methods, systems, and compositions of quantifying one or more analytes in a single sample volume without immobilization, separation, mass spectrometry, or melting curve analysis. Methods may comprise polymerase chain reaction and signal generation to quantify the analytes.

Abstract: The present disclosure provides methods and compositions for multiplex quantitation. In some aspects, methods and compositions are provided for quantitation of nucleic acid targets from a biological sample. The disclosed methods may be useful in identifying or detecting genetic abnormalities from a subject.

Abstract: The present disclosure provides methods and compositions for nucleic acid detection. Nucleic acids may be derived from any source including, for example, viruses, bacterial cells, and eukaryotic cells. The methods of the present disclosure may be used to detect the presence of at least one member of a plurality of nucleic acids in a sample. The methods of the present disclosure may be used to detect the presence of both a first and second member of a plurality of nucleic acids in a sample. Nucleic acids may be detected by the generation of one or more signals.

Abstract: The present disclosure provides methods and compositions for evaluation of nucleic acid size distribution and genetic abnormalities. The disclosed methods may be useful in determining size distribution of nucleic acids in a sample, for example, fetal fraction in a plasma sample. The disclosed methods may be useful in identifying or detecting genetic abnormalities from a subject, for example, fetal aneuploidy (e.g., trisomy 21).

Abstract: Methods for differentially quantifying nucleic acids in a biological sample using differentially methylated loci include forming a digested biological sample in a solution of a methylation-sensitive restriction enzyme to cleave an unmethylated group of nucleic acids, forming a reaction mixture, amplifying the reaction mixture to generate a first signal from the a group of detection probes and a second signal from a second group of detection probes, determining a ratio comprising a first value derived from the first signal to a second value derived from the second signal, and identifying the proportion of nucleic acid in the biological sample originating from the first plurality of nucleic acids.

Abstract: In one embodiment, a method includes extracting a cross-platform data-collection schema based, at least in part, on information available via heterogeneous interfaces of a plurality of source platforms. The cross-platform data-collection schema identifies a plurality of collectable data points in relation to particular source platforms. The method further includes configuring a cross-platform data-collection schedule for the plurality of source platforms. The cross-platform data-collection schedule indicates a collected subset of the plurality of collectable data points in relation to collection frequencies. The method also includes causing data values for the collected subset to be collected on an ongoing basis as dictated by the cross-platform data-collection schedule. Furthermore, the method includes processing a proposed change to at least one of the collected subset and the collection frequencies.

Abstract: The present disclosure provides methods and compositions for the multiplexed detection of multiple analytes from a sample. Analytes may be nucleic acid analytes. Detection of analytes may comprise contacting one or more sample subsets with hybridization probes, thereby generating one or more cumulative signal measurements capable of detecting the presence of absence of a plurality of analytes.

Abstract: The present disclosure provides methods and compositions for nucleic acid detection. Nucleic acids may be derived from any source including, for example, viruses, bacterial cells, and eukaryotic cells. The methods of the present disclosure may be used to detect the presence of at least one member of a plurality of nucleic acids in a sample. The methods of the present disclosure may be used to detect the presence of both a first and second member of a plurality of nucleic acids in a sample. Nucleic acids may be detected by the generation of one or more signals.

Abstract: The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that are specific for target cells, such as cancer cells. Further, the invention relates to methods of improving fusion proteins and to the improved fusion proteins.

Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.

Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.

Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the VH region, CH region, CL region, VL region, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in an E. coli expression system.